Source:http://linkedlifedata.com/resource/pubmed/id/16465399
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2006-2-8
|
| pubmed:abstractText |
Hepatocyte growth factor (HGF) is a promising agent for the treatment of liver cirrhosis because of its mitogenic and anti-fibrotic effects. We investigated the effect of recombinant human HGF (rh-HGF) on cirrhosis development; its pharmacokinetics and nephrotoxicity in rats with liver cirrhosis induced by 4-week treatment with dimethylnitrosamine (DMN). rh-HGF (0.3 mg/kg) was intravenously administered to rats once a day for 4 weeks in parallel with DMN treatment or twice a day for the last 2 weeks of DMN treatment. Repeated doses of rh-HGF increased the liver weight and serum albumin, and reduced serum ALT. The development of hepatic fibrosis was inhibited more efficiently by extended low-dose treatment with rh-HGF. In cirrhotic rats, serum levels of rh-HGF increased and clearance was decreased, leading to an increase in the area under the plasma-concentration time curve and a decrease in the steady-state volume of distribution. Repeated doses of rh-HGF led to increased urinary albumin excretion, but no rh-HGF-treated animals developed increased serum creatinine levels. Urinary albumin excretion returned to baseline after the cessation of rh-HGF. These results suggest that extended treatment with rh-HGF is required for the attenuation of cirrhosis, and repeated doses of rh-HGF cause adverse effects in extra-hepatic organs. These issues must be resolved before the widespread application of rh-HGF in the treatment of liver cirrhosis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Alanine Transaminase,
http://linkedlifedata.com/resource/pubmed/chemical/Dimethylnitrosamine,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatocyte Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Serum Albumin
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1107-3756
|
| pubmed:author |
pubmed-author:HasuikeSatoruS,
pubmed-author:IdoAkioA,
pubmed-author:InuiKen-IchiK,
pubmed-author:KatsuraToshiyaT,
pubmed-author:KimIldeokI,
pubmed-author:KodamaMayumiM,
pubmed-author:KusumotoKazunoriK,
pubmed-author:MoriuchiAkihiroA,
pubmed-author:NagataKenjiK,
pubmed-author:NumataMasatsuguM,
pubmed-author:TakahamaYukaY,
pubmed-author:TsubouchiHirohitoH,
pubmed-author:UtoHirofumiH
|
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
503-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16465399-Alanine Transaminase,
pubmed-meshheading:16465399-Albuminuria,
pubmed-meshheading:16465399-Animals,
pubmed-meshheading:16465399-Body Weight,
pubmed-meshheading:16465399-Dimethylnitrosamine,
pubmed-meshheading:16465399-Hepatectomy,
pubmed-meshheading:16465399-Hepatocyte Growth Factor,
pubmed-meshheading:16465399-Humans,
pubmed-meshheading:16465399-Injections, Intravenous,
pubmed-meshheading:16465399-Liver,
pubmed-meshheading:16465399-Liver Cirrhosis, Experimental,
pubmed-meshheading:16465399-Liver Regeneration,
pubmed-meshheading:16465399-Male,
pubmed-meshheading:16465399-Organ Size,
pubmed-meshheading:16465399-Rats,
pubmed-meshheading:16465399-Rats, Sprague-Dawley,
pubmed-meshheading:16465399-Recombinant Proteins,
pubmed-meshheading:16465399-Serum Albumin
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Repeated intravenous injection of recombinant human hepatocyte growth factor ameliorates liver cirrhosis but causes albuminuria in rats.
|
| pubmed:affiliation |
Department of Internal Medicine II, Faculty of Medicine, University of Miyazaki, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|